NCT05432713View on ClinicalTrials.gov

A Study of LP-168 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 14, 2022

Primary Completion Date

November 20, 2022

Study Completion Date

December 28, 2022

Conditions
Multiple SclerosisNMO Spectrum Disorder
Interventions
DRUG

LP-168 tablet

Lp-168 is a small molecule kinase inhibitor that is administered once daily via oral administration

DRUG

LP-168 Placebo tablet

LP-168 placebo tablets contain excipients for LP-168 tablets, but do not contain the active ingredients of the drug, and are used for comparison in clinical trials with the same usage and dosage as LP-168 tablets

Trial Locations (1)

310009

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Guangzhou Lupeng Pharmaceutical Company LTD.

INDUSTRY